Interleukin-6 Receptor Antagonist [EPC]

132120 reported adverse events

Drugs of this class: TOCILIZUMAB TOCILIZUMAB-AAZG SARILUMAB

These side effects are most commonly reported by patients taking drugs of the Interleukin-6 Receptor Antagonist [EPC] class:

# Side effect Count
0 DRUG INEFFECTIVE 38389
1 RHEUMATOID ARTHRITIS 24267
2 PAIN 23034
3 OFF LABEL USE 20629
4 ARTHRALGIA 20011
5 JOINT SWELLING 17970
6 FATIGUE 16086
7 RASH 14310
8 DRUG INTOLERANCE 13125
9 CONTRAINDICATED PRODUCT ADMINISTERED 12150
See all common reactions for Interleukin-6 Receptor Antagonist [EPC]

Drugs of the Interleukin-6 Receptor Antagonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 HUMAN ANTICHIMERIC ANTIBODY POSITIVE 310 0.9281
1 DISABILITY ASSESSMENT SCALE SCORE INCREASED 270 0.8738
2 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE 5938 0.8704
3 SWOLLEN JOINT COUNT INCREASED 2470 0.8370
4 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY 542 0.8287
5 RHEUMATOID FACTOR POSITIVE 4572 0.8179
6 RHEUMATIC FEVER 3329 0.8037
7 RHEUMATOID FACTOR NEGATIVE 138 0.7886
8 PEMPHIGUS 9194 0.7697
9 LUPUS VULGARIS 814 0.7558
See all enriched reactions for Interleukin-6 Receptor Antagonist [EPC]